NCT03518203View on ClinicalTrials.gov

Eculizumab to Treat Thrombotic Microangiopathy/Atypical Hemolytic Uremic Syndrome -Associated Multiple Organ Dysfunction Syndrome in Hematopoietic Stem Cell Transplant Recipients

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

August 3, 2018

Primary Completion Date

April 4, 2022

Study Completion Date

June 1, 2022

Conditions
Thrombotic MicroangiopathiesAtypical Hemolytic Uremic SyndromeMultiple Organ Dysfunction Syndrome
Interventions
DRUG

Eculizumab

Eculizumab will be administered as intravenous infusion (IV) over 60 minutes. The dosage form will be 300 mg single-use vials each containing 30 mL of 10 mg/mL sterile, preservative-free solution.

Trial Locations (3)

19104

Children's Hospital of Philadelphia (CHOP), Philadelphia

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

90027

Children's Hospital Los Angeles (CHLA), Los Angeles

All Listed Sponsors
lead

Children's Hospital Medical Center, Cincinnati

OTHER

NCT03518203 - Eculizumab to Treat Thrombotic Microangiopathy/Atypical Hemolytic Uremic Syndrome -Associated Multiple Organ Dysfunction Syndrome in Hematopoietic Stem Cell Transplant Recipients | Biotech Hunter | Biotech Hunter